MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

GlobeNewswire

2025/10/30

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.

MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

CONTACT: MannKind Contacts:
Investor Relations
Ana Kapor
Email: ir@mnkd.com

Media Relations
Christie Iacangelo
Email: media@mnkd.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579131009"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579131009\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579131009?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579131009","market":"us","top_or_hot":-1,"title":"MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025","media":"GlobeNewswire","content":"<html><body><p>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct.  29, 2025  (GLOBE NEWSWIRE) -- <strong>MannKind Corporation (Nasdaq: MNKD)</strong>, announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.</p> <p>MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.</p> <p><strong>About MannKind</strong><br/>MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.</p> <p>With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.</p> <p>Learn more at mannkindcorp.com.<br/></p> <pre>CONTACT: MannKind Contacts:\nInvestor Relations\nAna Kapor\nEmail: ir@mnkd.com\n\nMedia Relations\nChristie Iacangelo\nEmail: media@mnkd.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MjFjOGExOGMtMDBiNi00YTRjLWEwNTUtNjcxOGRkNzdjMWRiLTEwMTk2ODAtMjAyNS0xMC0yOS1lbg==/tiny/MannKind.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-10-30 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct.  29, 2025  (GLOBE NEWSWIRE) -- <strong>MannKind Corporation (Nasdaq: MNKD)</strong>, announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.</p> <p>MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.</p> <p><strong>About MannKind</strong><br/>MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.</p> <p>With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.</p> <p>Learn more at mannkindcorp.com.<br/></p> <pre>CONTACT: MannKind Contacts:\nInvestor Relations\nAna Kapor\nEmail: ir@mnkd.com\n\nMedia Relations\nChristie Iacangelo\nEmail: media@mnkd.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MjFjOGExOGMtMDBiNi00YTRjLWEwNTUtNjcxOGRkNzdjMWRiLTEwMTk2ODAtMjAyNS0xMC0yOS1lbg==/tiny/MannKind.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176846/29517/en/MannKind-Corporation-to-Hold-2025-Third-Quarter-Financial-Results-Conference-Call-on-November-5-2025.html","article_id":"2579131009","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579131009","pubTimestamp":1761768300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Investor Relations. Ana Kapor. Email: ir@mnkd.com. Media Relations. Christie Iacangelo. Email: media@mnkd.com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗","BK4584":"避孕概念","BK4139":"生物科技"},"translate_title":"MannKind Corporation将于2025年11月5日举行2025年第三季度财务业绩电话会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct.  29, 2025  (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. CONTACT: MannKind Contacts:\nInvestor Relations\nAna Kapor\nEmail: ir@mnkd.com\n\nMedia Relations\nChristie Iacangelo\nEmail: media@mnkd.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}